专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008005783A3 TREATMENT OF NON- INFECTIOUS INFLAMMATORY VULVOVAGINITIS WITH A BIOADHESIVE CLINDAMYCIN COMPOSITION 审中-公开
标题翻译：治疗非感染性炎症血管生成素与生物降解型蛋白质组合物
公开(公告)号：WO2008005783A3
公开(公告)日：2008-09-04
申请号：PCT/US2007072310
申请日：2007-06-28
申请人： DRUGTECH CORP , LEVINSON R SAUL , CUCA ROBERT C , BORTZ JONATHAN
发明人： LEVINSON R SAUL , CUCA ROBERT C , BORTZ JONATHAN
IPC分类号： A61K31/7056 , A61P15/02
CPC分类号： A61K31/7056 , A61K9/0034
摘要： A method for treating non-infectious inflammatory vulvovaginitis comprises administering to a vulvovaginal surface a pharmaceutical composition that comprises clindamycin in an amount of about 125 mg to about 400 mg per unit dose of the composition; wherein the composition is bioadhesive to the vulvovaginal surface, and upon application of the composition to the vulvovaginal surface the clindamycin is released over a period of about 3 hours to about 14 days. A related method comprises administering to a vulvovaginal surface a pharmaceutical composition comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, wherein the composition has at least one non-lipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. A pharmaceutical composition comprises (a) clindamycin or a pharmaceutically acceptable salt or ester thereof in a clindamycin equivalent amount of about 2.5% to about 4% by weight; and (b) a phospholipid or non-ionic ester surfactant; wherein the composition is a vaginal cream having at least one non-lipoidal internal phase and at least one lipoidal external phase that is bioadhesive to a vaginal mucosal surface.
摘要翻译：用于治疗非传染性炎症性外阴阴道炎的方法包括向外阴阴道表面施用药物组合物，其包含每单位剂量组合物约125mg至约400mg量的克林霉素; 其中所述组合物对外阴阴道表面具有生物粘附性，并且当将组合物施用于外阴阴道表面时，克林霉素在约3小时至约14天的时间内释放。相关方法包括向外阴阴道表面施用包含克林霉素或其药学上可接受的盐或酯的药物组合物，其中所述组合物具有至少一个非脂质内相和至少一个与外阴阴道表面生物粘附的脂质外相。药物组合物包含（a）克林霉素或其药学上可接受的盐或酯，其克林霉素当量为约2.5重量％至约4重量％; 和（b）磷脂或非离子酯表面活性剂; 其中所述组合物是具有至少一个非脂质内相和至少一个与阴道粘膜表面生物粘附的脂质外部相的阴道霜。

2. 发明申请

WO2008060764A2 TOPICAL THERAPIES FOR ORAL MUCOSITIS AND OTHER CONDITIONS 审中-公开
标题翻译：局部治疗口腔粘膜炎和其他病症
公开(公告)号：WO2008060764A2
公开(公告)日：2008-05-22
申请号：PCT/US2007080051
申请日：2007-10-01
申请人： DRUGTECH CORP , BORTZ JONATHAN , LEVINSON R SAUL , GE JISHENG , WANG JEREMY DONALD
发明人： BORTZ JONATHAN , LEVINSON R SAUL , GE JISHENG , WANG JEREMY DONALD
IPC分类号： A61K31/415 , A61K31/485 , A61P1/00 , A61P29/00
CPC分类号： A61K31/415 , A61K31/485
摘要： A method for treating oral mucositis in a subject comprises topically administering to an oral mucosal surface of the subject phenytoin or a pharmaceutically acceptable salt thereof in an amount effective to inhibit mucosal degeneration or promote mucosal regeneration, and optionally an analgesic agent in an amount effective, in combination with the phenytoin or salt thereof, to reduce pain associated with the oral mucositis. The phenytoin or salt thereof and optionally the analgesic agent can be administered in a pharmaceutical composition comprising an excipient vehicle suitable for intraoral administration, said composition being bioadhesive to an oral mucosal surface, for example having at least one non-lipoidal internal phase and at least one lipoidal external phase that is bioadhesive to said surface.
摘要翻译：一种用于治疗受试者的口腔粘膜炎的方法，包括以有效抑制粘膜变性或促进粘膜再生的量局部施用本发明苯妥英或其药学上可接受的盐的口腔粘膜表面以及有效量的镇痛剂，与苯妥英或其盐组合以减轻与口腔粘膜炎相关的疼痛。苯妥英或其盐和任选的止痛剂可以以包含适于口内给药的赋形剂赋形剂的药物组合物的形式给药，所述组合物是生物粘附于口腔粘膜表面的，例如具有至少一种非类脂内相，并且至少一个生物粘附于所述表面的类脂外相。

3. 发明申请

WO2007079390A3 MEDICAMENT FOR TOPICAL USE 审中-公开
标题翻译：用于局部使用的药物
公开(公告)号：WO2007079390A3
公开(公告)日：2007-11-15
申请号：PCT/US2006062658
申请日：2006-12-28
申请人： DRUGTECH CORP , BORTZ JONATHAN , LEVINSON R SAUL , KIRSCHNER MITCHELL , CUCA ROBERT C
发明人： BORTZ JONATHAN , LEVINSON R SAUL , KIRSCHNER MITCHELL , CUCA ROBERT C
IPC分类号： A61K9/107 , A61K31/415 , A61K31/4164 , A61K31/56 , A61K31/7036 , A61K39/395 , A61K45/06 , A61K48/00 , A61P31/04 , A61P31/10
CPC分类号： A61K31/7056 , A61K9/0034 , A61K31/00 , A61K31/4174 , A61K31/56 , A61K31/7034 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.
摘要翻译：药物组合物包含（a）抗菌有效量的抗菌剂，示例性地包括克林霉素或其药学上可接受的盐或酯; 和（b）抗真菌有效量的抗真菌剂，示例性地包含布康唑或其药学上可接受的盐或酯。该组合物适于以单位剂量施用于外阴阴道表面，并具有至少一种非类脂内相和至少一种生物粘附于外阴阴道表面的类脂外相。该组合物用于施用于外阴阴道表面以治疗混合细菌性阴道病和外阴阴道念珠菌感染。

4. 发明申请

WO2007084932A2 MIXED AMINO ACID/MINERAL COMPOUNDS HAVING IMPROVED SOLUBILITY 审中-公开
标题翻译：具有改善溶解性的混合氨基酸/矿物化合物
公开(公告)号：WO2007084932A2
公开(公告)日：2007-07-26
申请号：PCT/US2007/060656
申请日：2007-01-18
申请人： ALBION ADVANCED NUTRITION , DRUGTECH CORPORATION , THOMPSON, R., Charles , ERICSON, Clayton , ASHMEAD, Stephen , BORTZ, Jonathan
发明人： THOMPSON, R., Charles , ERICSON, Clayton , ASHMEAD, Stephen , BORTZ, Jonathan
IPC分类号： A23L1/30
CPC分类号： A23L33/175 , A23L33/16 , A23L33/165 , A23V2002/00 , A23V2250/1592 , A23V2250/1628 , A23V2250/044 , A23V2250/061 , A23V2250/0622
摘要： Mixed amino acid/mineral compounds can include at least two amino acids bound to a central mineral atom. The combination of amino acids can be tailored to provide improved solubility, absorption, and/or bioavailability of the mineral. Optionally, organic acids can be bound to the mineral or combined with the chelate in order to further improve solubility, absorption, and/or bioavailability. Compositions including one or more mixed amino acid/mineral compounds can be included in therapeutic regimens for indications in which the mineral may treat and/or prevent a condition or symptom.
摘要翻译：混合的氨基酸/矿物化合物可包括与中心矿物原子结合的至少两个氨基酸。可以调整氨基酸的组合以提供矿物质的改善的溶解度，吸收和/或生物利用度。任选地，有机酸可以与矿物结合或与螯合物结合，以进一步改善溶解度，吸收和/或生物利用度。包括一种或多种混合氨基酸/矿物质化合物的组合物可以包括在用于矿物可以治疗和/或预防病症或症状的适应症的治疗方案中。

5. 发明申请

WO2007070307A2 INTRAVENOUS ESSENTIAL FATTY ACID EMULSION 审中-公开
标题翻译：非特异性基质脂肪酸乳液
公开(公告)号：WO2007070307A2
公开(公告)日：2007-06-21
申请号：PCT/US2006/046551
申请日：2006-12-06
申请人： DRUGTECH CORPORATION , BORTZ, Jonathan, David , LEVINSON, R., Saul
发明人： BORTZ, Jonathan, David , LEVINSON, R., Saul
IPC分类号： A61K38/18 , A61K38/43 , A61K31/714 , A61K31/59 , A61K31/525 , A61K31/51 , A61K31/401 , A61K31/22 , A61K31/366 , A61K38/29
CPC分类号： A61K38/1816 , A61K9/0019 , A61K9/107 , A61K31/22 , A61K31/366 , A61K31/401 , A61K31/51 , A61K31/525 , A61K31/59 , A61K31/714 , A61K33/06 , A61K33/30 , A61K35/60 , A61K38/29 , A61K2300/00
摘要： A method for preventing stenosis and thrombosis of an AV graft is disclosed. An essential fatty acid emulsion is administered to the patient through the AV graft, preferably during dialysis, whereby the anti-inflammatory properties of the essential fatty acid emulsion prevent complications typical of AV grafts.
摘要翻译：公开了防止AV移植物的狭窄和血栓形成的方法。优选在透析期间通过AV移植物向患者施用必需脂肪酸乳剂，由此必需脂肪酸乳剂的抗炎特性防止AV移植物典型的并发症。

6. 发明申请

WO2007021805A3 ESTROGEN COMPOSITIONS AND THERAPEUTIC METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2007021805A3
公开(公告)日：2007-02-22
申请号：PCT/US2006/031153
申请日：2006-08-10
申请人： DRUGTECH CORPORATION , BORTZ, Jonathan , RILEY, Thomas, C.
发明人： BORTZ, Jonathan , RILEY, Thomas, C.
IPC分类号： A61K9/00 , A61K9/107 , A61K31/565 , A61K31/566 , A61K31/567 , A61P15/02
摘要： A pharmaceutical composition comprises at least one estrogenic compound, the composition being adapted for application in a unit dose amount to a vulvovaginal surface and having at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface, wherein the at least one estrogenic compound is present in an amount of about 5 to about 1000 μg estradiol equivalent per unit dose of the composition, and upon application of the composition to the vulvovaginal surface the at least one estrogenic compound is released over a period of about 3 hours to about 30 days. The composition is useful for vulvovaginal administration to treat atrophic vaginitis or a disorder associated therewith, for example in a menopausal or postmenopausal woman. A method for treating a hypoestrogenism-related condition of the urogenital system of a female patient comprises intravaginal administration of at least one estrogenic compound according to a treatment regimen wherein a series of compositions releasing a progressively increasing daily amount of the at least one estrogenic compound is administered over a period of at least about 1 month.

7. 发明申请

WO2006068697A3 COMPOSITIONS INCLUDING IRON 审中-公开
标题翻译：包括铁的组成
公开(公告)号：WO2006068697A3
公开(公告)日：2006-12-21
申请号：PCT/US2005038859
申请日：2005-10-27
申请人： DRUGTECH CORP , BORTZ JONATHAN DAVID , KIRSCHNER MITCHELL I , HERMELIN DAVID S
发明人： BORTZ JONATHAN DAVID , KIRSCHNER MITCHELL I , HERMELIN DAVID S
IPC分类号： A61K31/375 , A61K33/26
CPC分类号： A61K31/375 , A61K9/0053 , A61K31/19 , A61K31/191 , A61K31/194 , A61K31/295 , A61K31/341 , A61K33/26 , A61K2300/00
摘要： Nutritional or dietary supplement compositions that promote and/or maintain dietary iron absorption through administration of iron with an organic acid and optionally similar iron absorption promoters are provided. Also provided are methods of nutritional or dietary supplementation using one or more compositions that promote and/or maintain health through the prevention, stabilization, reversal and/or treatment of disorders associated with iron deficiency.
摘要翻译：提供了通过用有机酸和任选类似的铁吸收促进剂施用铁促进和/或维持膳食铁吸收的营养或膳食补充剂组合物。还提供了使用一种或多种通过预防，稳定，逆转和/或治疗与铁缺乏相关的疾病来促进和/或维持健康的营养或膳食补充的方法。

8. 发明申请

WO2006068697A2 COMPOSITIONS INCLUDING IRON 审中-公开
标题翻译：包含铁的组合物
公开(公告)号：WO2006068697A2
公开(公告)日：2006-06-29
申请号：PCT/US2005/038859
申请日：2005-10-27
申请人： DRUGTECH CORPORATION , BORTZ, Jonathan, David , KIRSCHNER, Mitchell, I. , HERMELIN, David, S.
发明人： BORTZ, Jonathan, David , KIRSCHNER, Mitchell, I. , HERMELIN, David, S.
IPC分类号： A61K33/26 , A61K31/19 , A61K31/375
CPC分类号： A61K31/375 , A61K9/0053 , A61K31/19 , A61K31/191 , A61K31/194 , A61K31/295 , A61K31/341 , A61K33/26 , A61K2300/00
摘要： Nutritional or dietary supplement compositions that promote and/or maintain dietary iron absorption through administration of iron with an organic acid and optionally similar iron absorption promoters are provided. Also provided are methods of nutritional or dietary supplementation using one or more compositions that promote and/or maintain health through the prevention, stabilization, reversal and/or treatment of disorders associated with iron deficiency.
摘要翻译：提供了通过用有机酸给予铁和任选相似的铁吸收促进剂来促进和/或维持膳食铁吸收的营养或膳食补充剂组合物。还提供了使用一种或多种通过预防，稳定，逆转和/或治疗与铁缺乏相关的病症来促进和/或维持健康的组合物的营养或膳食补充剂的方法。

9. 发明申请

WO2020236903A1 PHARMACEUTICAL FORMULATIONS AND METHODS FOR DELIVERING A THERAPEUTIC, DIAGNOSTIC, OR IMAGING AGENT TO CD206 审中-公开
公开(公告)号：WO2020236903A1
公开(公告)日：2020-11-26
申请号：PCT/US2020/033749
申请日：2020-05-20
申请人： SYRACUSE UNIVERSITY , XERAGENX LLC , BORTZ, Jonathan
发明人： BORTZ, Jonathan , DOYLE, Robert , WORKINGER, Jayme
IPC分类号： A23L33/15 , A61K31/4709 , A61K31/714 , A61P3/02 , C07H23/00
摘要： The present disclosure provides pharmaceutical formulations and methods for delivering a therapeutic, diagnostic, or imaging agent to CD206. In an aspect, the present disclosure encompasses a pharmaceutical formulation for administration. The pharmaceutical formulation comprises a recombinantly produced intrinsic factor (IF), wherein the IF has a glycosylation pattern that enables binding to CD206.

10. 发明申请

WO2009018514A1 DOSAGE FORM AND METHOD OF USE 审中-公开
标题翻译：剂型及使用方法
公开(公告)号：WO2009018514A1
公开(公告)日：2009-02-05
申请号：PCT/US2008/071900
申请日：2008-08-01
申请人： DRUGTECH CORPORATION , BORTZ, Jonathan, David , GRIMSHAW, Michael
发明人： BORTZ, Jonathan, David , GRIMSHAW, Michael
IPC分类号： A01N43/00 , A61K31/553
CPC分类号： A61K31/553
摘要： Methods for treating medical conditions for which quetiapine is indicated in a subject, comprising oral administration of quetiapine or a pharmaceutically acceptable salt thereof to treat said condition; wherein the dosage form comprises a major quetiapine component in immediate-release form in a sedative effective amount, administered prior to the start of a sleep period and either (i) a minor quetiapine component in extended-release, delayed extended-release or delayed pulsed-release form, wherein substantial onset of release of quetiapine is not earlier than about 6 hours after the start of the sleep period, or (ii) a plurality of minor quetiapine components in immediate-release form, administered sequentially during a waking period following the sleep period but not earlier than about 6 hours after the start of the sleep period; said minor component or components being administered in an anxiolytic effective amount insufficient to cause an unacceptable degree of sedation.
摘要翻译：用于治疗在受试者中显示喹硫平的医学病症的方法，包括口服施用喹硫平或其药学上可接受的盐以治疗所述病症; 其中所述剂型包含镇静有效量的立即释放形式的主要喹硫平组分，在睡眠期开始之前给予，以及（i）延长释放，延迟释放或延迟脉冲中的次要喹硫平组分释放形式，其中喹硫平的释放的实际开始不早于睡眠期开始后约6小时，或（ii）多个次要的喹硫平组分，其在即时释放形式中，在随后的醒来期间依次施用睡眠期不早于睡眠期开始后约6小时; 所述次要组分以不足以引起不可接受的镇静程度的抗焦虑有效量施用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式